Zambia

in page functions
[French]
Zambia
Total population (2018) 17,772,787
Birth cohort (2018) 688,257
Surviving Infants (surviving to 1 year per year, 2018) 656,927
Infant mortality rate (deaths < 1 year per 1000 births, 2015) 43/1000
Child mortality rate (deaths < 5 years per 1000 births, 2015) 64/1000
World Bank Index, IDA (2015) 3.29
Gross Nation Income (per capita US$, 2015) 1,490
Co-financing group (2018) Preparatory transition
No. of districts/territories (2017) 109

Contact Gavi

For more info, contact Gavi country representative officer or email here

Gavi support for Zambia

Type of support

Approvals

2001-2023 (US$)
(26 Sep 2018)

Commitments

2001-2023 (US$)
(26 Sep 2018)

Disbursements

2000-2018 (US$)
(26 Sep 2018)

% Disbursed

(26 Sep 2018)
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Total $158,799,091 $209,345,271 $158,208,139
Health system strengthening (HSS 1) $2,552,998 $2,552,998 $2,552,998 100%
Health system strengthening (HSS 2) $5,848,320 $10,500,000 $4,444,496 76%
HPV (NVS) $2,267,000 $9,202,000
Immunisation services support (ISS) $3,864,060 $3,864,060 $3,864,060 100%
Injection Safety Devices (NVS) $471,000 $1,124,000 $430,298 91%
Injection safety support (INS) $689,237 $689,237 $689,237 100%
IPV (NVS) $705,935 $705,935 $613,835 87%
Measles (NVS) $936,518 $936,518 $856,778 91%
Measles-Rubella (NVS) $5,439,180 $5,439,180 $5,439,180 100%
MR - Operational costs (OPC) $4,501,608 $4,501,608 $4,501,608 100%
Penta (NVS) $61,571,295 $68,524,295 $63,612,641 103%
Pneumo (NVS) $43,173,753 $66,274,753 $44,808,403 104%
Product Switch Grant (PSG) $204,986 $204,986
Rotavirus (NVS) $14,227,532 $22,480,032 $14,641,398 103%
Tetra DTP-Hib (NVS) $8,878,028 $8,878,028 $8,878,028 100%
Vaccine Introduction Grant (VIG) $3,467,641 $3,467,641 $2,875,179 83%

Red line on table indicates duration of support based on commitments.
Commitments: Multi-year programme budgets endorsed in principle by the Gavi Board. These become financial commitments upon approval each year for the following calendar year.
Approvals: Total Approved for funding

Download data for commitments, approvals & disbursements in XLS format

Zambia DTP3 / immunisation coverage

DTP3 - WHO/UNICEF estimates (2017)

Grade of confidence


N/A
DTP3 - Official country estimates (2017) 94%
M:F sex ratio at birth (2018) 1.03
Household survey: DTP3 coverage for male (2013) 86.40%
Household survey: DTP3 coverage for female (2013) 85.30%
Household survey: Last DTP3 survey (2013) 93%
% districts achieving > 80% DTP3 coverage (2017) 84%
% districts achieving < 50% DTP3 coverage (2017) 0%
MCV WHO/UNICEF estimates (2017) 96%

Breakdown of support

Non-vaccine support Vaccine support
12% 88%
$18,927,578 $139,280,561

Data refers to disbursed values, date as per above chart

Move mouse over graph for details

News and updates relating to Zambia

27 September 2018

Gavi at the 73rd UNGA

Gavi at the UNGA: driving political leadership

The 73rd United Nations General Assembly (UNGA) is a critical gathering for global health, with representatives from across the Vaccine Alliance working together to improve the health and wellbeing for millions of people worldwide.

10 September 2018

Vaccine heroes exhibit

Vaccine Heroes

A new Gavi photo exhibition in Geneva celebrates the health workers, campaigners, scientists and parents who reach millions of children with life-saving vaccines every year.

31 July 2018

INFUSE workshop

Fingerprint records and digital health cards to help solve global identity crisis

Four companies will receive Gavi support to help scale emerging digital identification technologies in developing countries.

Disclaimer: the boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of Gavi, the Vaccine Alliance concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

close icon

modal window here